ArticleCase reports in neurology
Deep Brain Stimulation Withdrawal Syndrome in Parkinson's Disease: Clinical Features and Outcomes of Two New Cases.
Article in Case reports in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Deep brain stimulation (DBS) withdrawal syndrome is a rare but potentially fatal complication in Parkinson's disease (PD), manifesting as akinetic crisis with severe rigidity, fever, autonomic instability, altered mental status, and elevated creatinine kinase (CK) levels. The syndrome is strongly associated with older age, long duration of the disease (>15 years), and the duration of DBS therapy (>5 years), with most reported cases having at least two of these risk factors. However, all available evidence comes from a limited number of case reports. Case Presentations: We report two cases of DBS withdrawal syndrome, including a patient without any of the currently acknowledged risk factors. This patient, in their late 50s with young-onset PD, was treated with bilateral subthalamic nucleus DBS with a good response, although requiring high stimulation amplitude (4.1 V bilaterally). The first patient developed an akinetic crisis after battery depletion at a PD duration of 11 years and a DBS duration of 4 years. Implantable pulse generator (IPG) replacement was performed 14 days later, resulting in permanent disability and, eventually, death. The second patient, in their mid-60s with long-standing PD and DBS therapy for 14 years, presented with a severe akinetic crisis and markedly elevated CK. IPG replacement within 2 days led to full recovery. Conclusion: DBS withdrawal syndrome can occur without the typical risk profile, and high stimulation amplitude may represent an additional risk factor. Early recognition and immediate DBS therapy restoration are critical to prevent severe, potentially fatal outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.